Notification of Somatuline LA 30mg discontinuation

IPSEN has notified the Therapeutic Goods Administration (TGA) that as of 15th December, 2020, Somatuline® LA 30mg (lanreotide acetate) will no longer be supplied in Australia (due to the low volume of requests and the presence of a suitable replacement, Somatuline® Autogel®). A notice of the discontinuation of the product will be published on both the IPSEN Australia website and the TGA website. Somatuline® LA 30mg is currently approved for the treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory. 1 To ensure ongoing supply of lanreotide to Australian patients, IPSEN have an alternate presentation of lanreotide: Somatuline® Autogel® (lanreotide as acetate) in 60mg/90mg/120mg solution for injection in a ready-to-use prefilled syringe2 . The indications 2 for Somatuline® Autogel® are:

• the treatment of acromegaly when the circulating levels of growth hormone and IGF-1 remain abnormal after surgery and/or radiotherapy or in patients who are dopamine agonist treatment refractory

• the treatment of symptoms of carcinoid syndrome associated with carcinoid tumours

• the treatment of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adult patients with unresectable locally advanced or metastatic disease.

While the formulations are different, the active ingredient of Somatuline® LA 30mg and Somatuline® Autogel® 60mg/90mg/120mg solution for injection prefilled syringe, is identical (lanreotide acetate) 1,2 . Somatuline® LA is formulated as a prolonged-release depot suspension for intramuscular injection1 . Somatuline® Autogel® is formulated as a prolonged-release solution for deep subcutaneous injection2 . In patients previously treated with Somatuline® LA once every 14 days for acromegaly, the initial dose of Somatuline® Autogel® should be 60mg every 28 days. Please refer to the Somatuline® Autogel® Product Information for more information on transitioning patients2 . Somatuline® Autogel® is available on the Pharmaceutical Benefits Scheme. Additional detail is provided below, however we recommend that you consult the PBS (www.pbs.gov.au) for further information regarding the availability of Somatuline® Autogel®.

Should you require further information regarding the discontinuation of Somatuline® LA 30mg, please contact the IPSEN Medical Information Department on 1800 317 033.

IPSEN PTY LTD ABN 47 095 036 909
BRANDON OFFICE PARK, LEVEL 2, BUILDING 4, 540 SPRINGVALE ROAD, GLEN WAVERLEY VIC 3150, AUSTRALIA
TELEPHONE: +61 (0)3 8544 8100 • FAX: +61 (0)3 9562 5152 EMAIL: INFO@IPSEN.COM.AU
DATE OF PREPARATION: JANUARY 2019. ALL-AU-000008
© Ipsen Group 2019